Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice

✍ Scribed by Maria-Ana Ghetie; James Richardson; Thomas Tucker; Diane Jones; Jonathan W. Uhr; Ellen S. Vitetta

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: French
• Weight: 626 KB
• Volume: 45
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910450318

✦ Synopsis

Abstract

A human Burkitt lymphoma (Daudi) has been grown in the mutant mouse called C.B‐17 SCID. Twenty‐eight days after s.c. injection of Daudi cells, a palpable tumor grew only at the site of injection in all injected mice. In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated tumors developed. Following i.v. inoculation, tumors grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic tumor infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the tumors were localized in the abdomen, liver, spieen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow. The growth pattern and phenotype of the Daudi cells were similar whether the inoculated tumor cells were derived from the in vitro cell line or from in vivo passaged tumors. The survival time of the tumor‐bearing animals was dependent on the dose of i.v.‐administered Daudi cells; as few as 100 cells caused death. All mice injected i.v. showed paresis or paralysis of the hind legs just prior to death. This was associated with the presence of neoplastic nodules within the spinal canal. Two surface antigens on Daudi cells (CD19 and CD22) were stably expressed in all the neoplastic lesions. Radiolabelled anti‐CD22 antibodies localized in organs infiltrated with tumor, but did not penetrate primary s.c. tumors.

This model of disseminated vs. solid tumor should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti‐human B‐cell antibodies.